Surrozen (NASDAQ:SRZN) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Surrozen (NASDAQ:SRZN) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $40.00 target price on the stock.

A number of other analysts have also commented on SRZN. Wall Street Zen raised Surrozen to a “sell” rating in a research note on Friday, November 28th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective (up from $32.00) on shares of Surrozen in a report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.00.

Surrozen Stock Performance

Shares of SRZN opened at $25.00 on Tuesday. Surrozen has a 52 week low of $5.90 and a 52 week high of $29.59. The stock has a market capitalization of $214.28 million, a price-to-earnings ratio of -0.75 and a beta of 0.53. The stock has a fifty day moving average of $24.21 and a 200-day moving average of $18.76.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($23.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.29) by ($22.59). Surrozen had a negative return on equity of 1,240.42% and a negative net margin of 7,476.67%.The firm had revenue of $0.53 million for the quarter, compared to the consensus estimate of $0.66 million. As a group, equities analysts forecast that Surrozen will post -8.49 EPS for the current year.

Insider Activity

In related news, Director Tim Kutzkey acquired 18,052 shares of the stock in a transaction dated Tuesday, January 20th. The stock was bought at an average cost of $19.60 per share, for a total transaction of $353,819.20. Following the completion of the transaction, the director directly owned 1,016,658 shares of the company’s stock, valued at $19,926,496.80. The trade was a 1.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Group Gp Lp Column III acquired 18,052 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was bought at an average cost of $19.60 per share, for a total transaction of $353,819.20. Following the completion of the purchase, the insider owned 1,016,658 shares of the company’s stock, valued at $19,926,496.80. This trade represents a 1.81% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 208,410 shares of company stock valued at $4,466,346. Company insiders own 43.50% of the company’s stock.

Institutional Investors Weigh In On Surrozen

A number of institutional investors have recently modified their holdings of the company. Millennium Management LLC increased its position in shares of Surrozen by 557.1% during the fourth quarter. Millennium Management LLC now owns 721,266 shares of the company’s stock worth $16,301,000 after buying an additional 611,497 shares during the period. Stempoint Capital LP lifted its holdings in Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares during the period. Spruce Street Capital LP bought a new stake in Surrozen during the fourth quarter valued at $9,764,000. Kalehua Capital Management LLC bought a new stake in Surrozen during the fourth quarter valued at $8,705,000. Finally, Braidwell LP grew its holdings in Surrozen by 235.7% during the 4th quarter. Braidwell LP now owns 470,000 shares of the company’s stock worth $10,622,000 after acquiring an additional 330,000 shares during the period. 66.57% of the stock is owned by institutional investors.

More Surrozen News

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Cantor Fitzgerald reaffirmed an “overweight” rating and set a $40 price target (implies ~60% upside versus current levels). Article Title
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and raised its price target to $36 from $32 (roughly ~44% upside). Article Title Ticker Report
• Positive Sentiment: Corporate update: Surrozen expects to submit an IND for SZN-8141 in H2 2026, will present retinal vascular research at ARVO 2026, and earned a $5M milestone payment from Boehringer Ingelheim for SZN-413 — all near-term program and partnership milestones that could meaningfully de‑risk upcoming value inflection points. Press Release
• Neutral Sentiment: Short-interest reports for March show anomalous/zero values (0 shares reported, days-to-cover ~0.0) across multiple snapshots — this data appears inconsistent and provides little actionable signal about current short pressure. (No external link provided.)
• Negative Sentiment: Q4 / FY2025 results: Surrozen reported a very large EPS miss — ($23.88) vs. consensus (~($1.29)) — and continued negative margins/ROE; revenue of $0.53M missed expectations. The magnitude of the miss is the primary near-term driver of the stock decline. Earnings Release

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.